House File 2223 - Introduced



                                      HOUSE FILE       
                                      BY  HEATON, L. MILLER, GRANZOW,
                                          TOMENGA, and UPMEYER


    Passed House, Date               Passed Senate, Date             
    Vote:  Ayes        Nays           Vote:  Ayes        Nays         
                 Approved                            

                                      A BILL FOR

  1 An Act relating to the disclosure of relationships with
  2    pharmaceutical manufacturers by members of the medical
  3    assistance pharmaceutical and therapeutics committee and the
  4    drug utilization review commission.
  5 BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF IOWA:
  6 TLSB 5111YH 82
  7 pf/nh/14

PAG LIN



  1  1    Section 1.  Section 249A.20A, subsection 2, Code 2007, is
  1  2 amended by adding the following new paragraph:
  1  3    NEW PARAGRAPH.  d.  A member of the committee shall
  1  4 disclose to the department, in a format and in accordance with
  1  5 a schedule prescribed by rule of the department, any financial
  1  6 relationship or affiliation with a pharmaceutical
  1  7 manufacturer, including but not limited to any payments or
  1  8 contributions for lectures, consulting, research, or other
  1  9 services.
  1 10    Sec. 2.  Section 249A.24, Code 2007, is amended by adding
  1 11 the following new subsection:
  1 12    NEW SUBSECTION.  4.  A member of the commission shall
  1 13 disclose to the department, in a format and in accordance with
  1 14 a schedule prescribed by rule of the department, any financial
  1 15 relationship or affiliation with a pharmaceutical
  1 16 manufacturer, including but not limited to any payments or
  1 17 contributions for lectures, consulting, research, or other
  1 18 services.
  1 19                           EXPLANATION
  1 20    This bill requires a member of the medical assistance
  1 21 pharmaceutical and therapeutics committee or a member of the
  1 22 medical assistance drug utilization review commission to
  1 23 disclose to the department of human services any financial
  1 24 relationship or affiliation with a pharmaceutical
  1 25 manufacturer, including but not limited to any payments or
  1 26 contributions for lectures, consulting, research, or other
  1 27 services.  The members are to disclose the information in a
  1 28 format and in accordance with a schedule prescribed by rule of
  1 29 the department of human services.
  1 30 LSB 5111YH 82
  1 31 pf/nh/14.1